SVT-15473の新興薬剤に関する洞察と市場予測：2032年

SVT-15473は、超強力ステロイドであるプロピオン酸クロベタゾールの新規かつ革新的な眼科用ナノ乳剤であり、眼科領域で使用される初の超強力ステロイドとなる可能性が高いものです。さらに、サルバット社独自のIMPACT-SVT技術によりナノエマルジョンとして製剤化され、1回用量バイアルに充填されているため、市販されている他の代替品よりも優れた利点を有しています。有効性と安全性に加え、臨床試験では他の副腎皮質ステロイドと異なり眼圧を上昇させないことが示されています。SVT-15473は、眼科手術後の患者の炎症と疼痛の管理薬としてFDAに承認申請中です。

今後数年間で、急性眼痛の市場シナリオは、世界中の研究な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、SVT-15473の優位性に影響を与える可能性のある機会を模索しています。急性眼痛に対する他の新興製品がSVT-15473に厳しい市場競争を与えることが予想され、近い将来、後発の新興治療薬の発売が市場に大きな影響を与えるとみられています。

当レポートでは、主要8ヶ国におけるSVT-15473市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性眼痛に対するSVT-15473の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 SVT-15473市場評価

• 急性眼痛に対するSVT-15473の市場展望
• 主要8ヶ国市場分析
  • 主要8ヶ国市場における急性眼痛に対するSVT-15473の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • カナダ
  • 韓国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: SVT-15473, Clinical Trial Description, 2023
• Table 2: SVT-15473, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: SVT-15473 Market Size in the 8MM, in USD million (2019-2032)
• Table 6: SVT-15473 Market Size in the US, in USD million (2019-2032)
• Table 7: SVT-15473 Market Size in Germany, in USD million (2019-2032)
• Table 8: SVT-15473 Market Size in France, in USD million (2019-2032)
• Table 9: SVT-15473 Market Size in Italy, in USD million (2019-2032)
• Table 10: SVT-15473 Market Size in Spain, in USD million (2019-2032)
• Table 11: SVT-15473 Market Size in the UK, in USD million (2019-2032)
• Table 12: SVT-15473 Market Size in Canada, in USD million (2019-2032)
• Table 13: SVT-15473 Market Size in South Korea, in USD million (2019-2032)

List of Figures

• Figure 1: SVT-15473 Market Size in the 8MM, USD million (2019-2032)
• Figure 2: SVT-15473 Market Size in the United States, USD million (2019-2032)
• Figure 3: SVT-15473 Market Size in Germany, USD million (2019-2032)
• Figure 4: SVT-15473 Market Size in France, USD million (2019-2032)
• Figure 5: SVT-15473 Market Size in Italy, USD million (2019-2032)
• Figure 6: SVT-15473 Market Size in Spain, USD million (2019-2032)
• Figure 7: SVT-15473 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: SVT-15473 Market Size in Canada, USD million (2019-2032)
• Figure 9: SVT-15473 Market Size in South Korea, USD million (2019-2032)

“"SVT-15473 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SVT-15473 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the SVT-15473 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SVT-15473 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SVT-15473 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

SVT-15473 is a new and innovative ocular nano-emulsion of super-potent steroid clobetasol propionate, which will likely be the first ultra-potent steroid to use in the field of ophthalmology. Moreover, its formulation as a nano-emulsion with Salvat's proprietary IMPACT-SVT technology and its presentation in single-dose vials offers superior advantages over other alternatives on the market. In addition to its efficacy and safety, clinical trials have shown that, unlike other corticosteroids, it does not increase intra-ocular pressure. The company has filed an NDA to the FDA for the approval of SVT-15473 in managing inflammation and pain in post-ocular surgery patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SVT-15473 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
• Elaborated details on SVT-15473 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SVT-15473 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
• The report also covers the patents information with expiry timeline around SVT-15473.
• The report contains forecasted sales of SVT-15473 for acute ocular pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
• The report also features the SWOT analysis with analyst views for SVT-15473 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SVT-15473 Analytical Perspective by DelveInsight

In-depth SVT-15473 Market Assessment

This report provides a detailed market assessment of SVT-15473 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

SVT-15473 Clinical Assessment

The report provides the clinical trials information of SVT-15473 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SVT-15473 dominance.
• Other emerging products for acute ocular pain are expected to give tough market competition to SVT-15473 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SVT-15473 in acute ocular pain.
• Our in-depth analysis of the forecasted sales data of SVT-15473 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SVT-15473 in acute ocular pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of SVT-15473?
• What is the clinical trial status of the study related to SVT-15473 in acute ocular pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SVT-15473 development?
• What are the key designations that have been granted to SVT-15473 for acute ocular pain?
• What is the forecasted market scenario of SVT-15473 for acute ocular pain?
• What are the forecasted sales of SVT-15473 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
• What are the other emerging products available and how are these giving competition to SVT-15473 for acute ocular pain?
• Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?

Table of Contents

1. Report Introduction

2. SVT-15473 Overview in Acute ocular pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SVT-15473 Market Assessment

• 5.1. Market Outlook of SVT-15473 in Acute ocular pain
• 5.2. 8MM Analysis
  • 5.2.1. Market Size of SVT-15473 in the 8MM for Acute ocular pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SVT-15473 in the United States for Acute ocular pain
  • 5.3.2. Market Size of SVT-15473 in Germany for Acute ocular pain
  • 5.3.3. Market Size of SVT-15473 in France for Acute ocular pain
  • 5.3.4. Market Size of SVT-15473 in Italy for Acute ocular pain
  • 5.3.5. Market Size of SVT-15473 in Spain for Acute ocular pain
  • 5.3.6. Market Size of SVT-15473 in the United Kingdom for Acute ocular pain
  • 5.3.7. Market Size of SVT-15473 in Canada for Acute ocular pain
  • 5.3.8. Market Size of SVT-15473 in South Korea for Acute ocular pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options